SAN DIEGO, May 7, 2015 /PRNewswire/ — Antiplatelet drug ticagrelor (Brilinta®) works faster and is more effective in blocking platelet activity in low-risk patients with acute coronary syndrome (ACS) than clopidogrel, according to a new study presented today as a late-breaking clinical trial at the Society for Cardiovascular Angiography and Interventions (SCAI) 2015 Scientific Sessions in San Diego.
Ticagrelor was approved by the U.S. Food and Drug Administration in 2011 based on results from the PLATO trial, which compared ticagrelor to clopidogrel in patients pre-treated with one of the medications plus aspirin prior to percutaneous coronary intervention (PCI). However, many low-risk ACS patients undergoing “ad hoc” PCI, or PCI following a diagnostic catheterization, are not pre-treated with an antiplatelet drug.
In the trial presented today, 100 patients were randomized to receive either ticagrelor (180 mg loading dose and 90 mg after 12 hours) or clopidogrel (600 mg loading dose) with aspirin (75-100 mg daily) at the time of PCI. All of the patients tested negative for troponin, a substance in the blood indicating damage to the heart muscle. Researchers measured platelet reactivity prior to receiving the medication; at 0.50, two- and eight-hour intervals; and at the end of PCI. The primary endpoint of the study was platelet reactivity at two hours.
The study found platelet activity differed as early as one-half hour after the medication was administered. Significant reduction in platelet activity began as early as the end of PCI, which occurred a mean 0.6 hours after the medication was given, and continued to decrease at eight hours.
“At standard doses, ticagrelor works faster and better inhibits platelet activity than clopidogrel in low- risk ACS patients,” said Roxana Mehran, MD, FSCAI, director of cardiovascular research and interventional clinical trials at Mount Sinai Medical Center in New York, and the study’s principal investigator. “The study suggests low-risk patients undergoing ad hoc PCI may fare better with ticagrelor.”
Dr. Mehran has received research grants from DSI/Eli Lilly, Bristol-Myers Squibb/Sanofi-Aventis, AstraZeneca, and The Medicines Company; and consulting or advisory board fees from AstraZeneca, Bayer, CSL Behring, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Osprey Medical Inc., Regado Biosciences, Inc., The Medicines Company, Watermark Consulting, Abbott Laboratories, Boston Scientific, Covidien, and Sanofi-Aventis.
Dr. Mehran presented “Ticagrelor versus Clopidogrel in Troponin-negative Patients with Acute Coronary Syndrome Undergoing Ad Hoc Percutaneous Coronary Intervention: Results of a Prospective, Randomized, Multicenter Pharmacodynamic Study,” on Thursday, May 7, 2015, at 11:30 a.m. (Pacific Time).
The Society for Cardiovascular Angiography and Interventions is a 4,500-member professional organization representing invasive and interventional cardiologists in approximately 70 nations. SCAI’s mission is to promote excellence in invasive/interventional cardiovascular medicine through physician education and representation, and advancement of quality standards to enhance patient care. SCAI’s public education program, Seconds Count, offers comprehensive information about cardiovascular disease. For more information about SCAI and Seconds Count, visit www.SCAI.org or www.SecondsCount.org. Follow @SCAI and @SCAINews on Twitter for the latest heart health news. Use #SCAI2015 to stay up-to-date and join the annual meeting conversation.
Source: PR Newswire Health